A Randomized placebo clinical study and life style interventionon Mesha Shringyadi Gugglu in Medovridhhi

Phase 1

Not yet recruiting

Conditions: Patient with hypertryglyceridemia

Registration Number: CTRI/2016/03/006709

Lead Sponsor: IPGT and RA Gau Jamnagar

Brief Summary: **A randomied placebo controlled clinical study was carried out to evaluate the role of cap. Meshashringyadi Guggulu and life style intervention in the management of Hypertriglyceridemia (Medo Vriddhi). Approval of IEC (Ref No: PGT/7-A/ETHICS/2015-16/1490) dated 25.08.2015. The study has also been registered in CTRI (CTRI/2016/03/006709) on 04 .03 2016. Clinically diagnosed 45 patients were registered after taking written consent and randomly divided into two groups. In trial group 20 patients completed the treatment and 3 patients drooped out. In placebo group also 20 patients completed treatment and 2 patients dropped out. In trial group and placebo group patients were given Meshashringyadi Guggulu capsule and Sooji powder capsule respectively, 2 cap. thrice daily before breakfast, lunch and dinner with luke warm water for duration of 8 weeks. On completion of 8 weeks treatment, the trial grp and placebo grp provided 33.21% and 24.91% decrease in S. tryglyceride. In trial group complete remission was obserbed in 35%, marked improvement was obserbed in 25%, moderate improvement was obserbed in 15% and 10% remained unchanged while in placebo group complete remission was obserbed in 25%, marked imrovement in 30%, moderate improvement in 10%, mild improvement in 45%, 15% remained unchanged and 5% patients deteriorated during the clinical study.**

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 40

Inclusion Criteria

S.cholesterol >200mg/dl or/and S.Triglyceride >150mg/dl or/and S.L.D.L >130mg/dl or /and S.H.D.L <40mg/dl.

Exclusion Criteria

Age below 25 and above 60 years Patients suffering from type 1 dm and uncotrolled dm patients having uncontrolled hypertention past history of MI unstabe angina renal disese liver disease.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
to show changes in lipid proofile mainly S triglyceride level	to show changes in lipid proofile mainly S triglyceride level

Secondary Outcome Measures

Name	Time	Method
â€¢By providing better effect on hypertriglyceridemia,drug may also reduce the risk of insuline resistance diabetes, metabolic syndrome, pancreatitis & IHD.	Cange in lipid profile

Trial Locations

Locations (1): IPGTand Ra GAU Jmanagar
🇮🇳
Jamnagar, GUJARAT, India
IPGTand Ra GAU Jmanagar
🇮🇳Jamnagar, GUJARAT, India
Dr mandip Goyal
Principal investigator
9978403467
kaurmandip22@yahoo.com